Prograf-Advagraf Cross Over Conversion Study
|ClinicalTrials.gov Identifier: NCT01797341|
Recruitment Status : Completed
First Posted : February 22, 2013
Last Update Posted : September 18, 2014
|Condition or disease||Intervention/treatment||Phase|
|Kidney-Pancreas Transplantation||Drug: Tacrolimus||Phase 3|
Tacrolimus (Prograf ©) has become part of the standard of care for patients receiving solid organ transplants and is part of the immunosuppressive protocol used by kidney-pancreas transplant recipients at University Health Network (UHN). Tacrolimus is associated with several toxicities, and as a result, careful therapeutic drug monitoring of tacrolimus is a key component of post-transplant management. Trough serum concentrations of tacrolimus are measured routinely and are used to guide dosing. Tacrolimus trough levels are known to correlate with total drug exposure. The Prograf formulation of tacrolimus has a fairly short serum half-life and must be dosed twice daily to maintain therapeutic serum concentrations. This results in two high peak levels each day which have been shown to correlate with toxicity. Thus, avoidance of high peaks may be desirable to minimize tacrolimus toxicity.
Advagraf is a new preparation of tacrolimus that is formulated to provide similar drug exposure to tacrolimus but with a once daily dosing regimen, which avoids the 2 daily high tacrolimus peaks observed with Prograf. In this way, it is hoped that Advagraf may provide similar therapeutic efficacy as Prograf but with fewer adverse effects. In addition, the simpler dosing regimen is expected to enhance patient adherence. Tacrolimus has also been shown, along with many other drugs, to have a variable impact on mycophenolate acid (MPA) pharmacokinetics. There are currently few data on whether Advagraf impacts MPA pharmacokinetics to the same or a lesser degree than Prograf.
Eligible kidney-pancreas recipients will be recruited and after obtaining informed consent, randomized to continue their current total daily Prograf dosage or switch to the equivalent once daily dose of Advagraf. Patients will continue randomized therapy for 12 weeks and will then cross over to the opposite therapy for another 12 weeks. Patients will be followed and maintained on the same medication designated at week 24. Bloodwork results, adherence and AEs (adverse events) will be assessed.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||13 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Official Title:||Prograf/Advagraf Conversion Study in Kidney Pancreas Transplant Recipients|
|Study Start Date :||June 2013|
|Actual Primary Completion Date :||February 2014|
|Actual Study Completion Date :||February 2014|
Experimental: Prograf arm
patients will self-administer tacrolimus in the form of Prograf (twice daily administration.
Dosage will be adjusted to maintain trough serum levels of 5-15 μg/ml. Maximum daily dose of 20 mg once per day.
Other Name: Prograf
Experimental: Advagraf Arm
patients will self-administer tacrolimus in the form of Advagraf (once daily dosing) Dosage will be adjusted to maintain trough serum levels of 5-15 μg/ml. Maximum daily dose of 20 mg once per day.
Other Name: Advagraf
- Tacrolimus trough levels [ Time Frame: prior to conversion and 12 weeks post-conversion ]Serum trough levels
- Change in Renal Function [ Time Frame: prior to conversion and 12 weeks post-conversion ]Serum creatinine and urea levels
- Change in Tacrolimus dosage (week 12 compared to week 24) [ Time Frame: week 12 and week 24 ]
- Change in Fasting glucose [ Time Frame: prior to conversion and 12 weeks post-conversion ]serum fasting glucose levels
- Lipid profile [ Time Frame: prior to conversion and 12 weeks post-conversion ]Cholesterol, etc...
- blood pressure [ Time Frame: prior to conversion and 12 weeks post-conversion ]Cuff blood pressure readings
- Drug Adherence [ Time Frame: assessed at weeks 12 and 24 ]patient self-reported drug adherence
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability" [ Time Frame: at week 12 and week 24 ]at every visit, patients will be asked about and assessed for any adverse event development
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01797341
|Toronto General Hospital|
|Toronto, Ontario, Canada, M5G 2N2|
|Principal Investigator:||Mark S Cattral, MD||University Health Network, Toronto|